原发性乳腺恶性淋巴瘤28例

[目的]探讨原发性乳腺恶性淋巴瘤(PBL)的临床病理特点、诊治方法.[方法]回顾性分析28例原发性乳腺恶性淋巴瘤临床资料,中位年龄46岁(30～70岁).按照Ann Arbor分期标准,Ⅰ EA期14例,ⅡEA期8例,ⅢEA期3例,ⅢEB期l例,ⅣEA期2例;其中B细胞来源25例,外周T细胞来源3例.治疗情况:单纯手术组2例,单纯化疗组2例,综合治疗组24例;化疗一般采用CHOP方案,4～8个周期.[结果]随访时间6～139个月,中位随访时间62.5个月,全组患者中位生存时间为66个月(95％CI:50～84),5年生存率为45.6％.[结论]PBL病理以B细胞来源最常见.目前多选择化疗及放疗为基础结合手术的综合治疗,但仍有待多中心随机对照研究加以证实.     

原发性乳腺恶性淋巴瘤13例临床分析

目的：回顾性分析原发性乳腺恶性淋巴瘤的发病，诊断，治疗与预后。方法：收集我院1985年1月至2000年12月13例原发性乳腺恶性淋巴瘤进行回顾性分析。结果：13例均为弥漫型非何杰金氏淋巴瘤，占同期乳隙恶性肿瘤的0.35%。7例行乳腺癌根治术或改良根治术，术后化疗，5年生存率为52.0%；4例行局部切除术加化疗和/或放疗，2例复发，2例单纯化疗，总的5年生存率为47%。结论：肿块细针穿刺涂片未能确诊、光镜下组织学检查可确诊，免疫组化检查可进一步确定诊断。本病在局部治疗的基础上加全身化疗，效果良好；手术切除局部治疗效果良好。可作为首选，预后与临床分期和治疗措施是否得当有关。     

20例原发睾丸淋巴瘤的临床分析

目的：分析原发睾丸淋巴瘤的预后，提出治疗方法。方法：回顾性分析了20例患者，按Ann Arbor分期标准，ⅠE期9例，ⅡE期2例，Ⅲ-Ⅳ期9例。结果：全组5年，10年生存率分别为30．0％和25．0％，ⅠE，ⅡE期5年，10年生存率54．5％，45．5％，Ⅲ，Ⅳ期5年，10年生存率为0。结论：经综合治疗，睾丸淋巴瘤的预后明显改善。建议对早期睾丸淋巴瘤行术后正规，足量化疗。     

结外原发非霍奇金淋巴瘤55例临床分析

本文报告了1990～1995年间经穿刺细胞学病理诊断的结外非霍奇金淋巴瘤55例。发病部位以咽淋巴环和胃肠道为多，占50．90％；其临床表现复杂多样，易误诊和漏诊。我们认为穿刺细胞学病理诊断对减少误诊率、提高治愈率具有重要作用。     

Primary Liver Lymphoma: A Case Report with Review of Literature

Primary non-Hodgkin's lymphoma of the liver is exceedingly rare and until now only 53 cases have been recorded. Most extranodal non-Hodgkin's lymphomas are in the head and neck region and the gastrointestinal tract. We report a patient with primary non-Hodgkin's lymphoma of the liver and also review the relevant literature.     

21例原发性乳腺非霍奇金淋巴瘤临床分析

目的:分析原发性乳腺非霍奇金淋巴瘤(PBNHL)的临床特征、治疗与预后,增加对该罕见病的认识.方法:回顾性分析1985年1月～2003年12月本院21例PBNHL的临床特点、治疗经过和随访结果.结果:21例PBNHL,女20例,男1例,中位年龄36岁(21～84岁).90%Ann Arbor分期为Ⅰ～Ⅱ期,所有患者预后分级均为低危或低中危.病理类型B细胞性87%,外周T细胞性13%.弥漫大B细胞性占53%.8例接受乳腺癌根治术或改良根治术,13例为肿块切除或活检;20例患者接受CHOP方案化疗;4例于化疗后局部放疗.患者双侧乳腺同时或先后发病占33%(7/21),CNS受累比例为14%.随访时间3～116月,中位17个月.中位总生存期和无事件生存期为26个月和12个月,5年总生存率和无事件生存率为39%和19%.结论:PBNHL病理以弥漫大B细胞性最常见,低度恶性NHL少见.CNS侵犯或复发是PBNHL的重要特征,对侧乳腺复发是接受患侧乳腺癌根治术或放疗的患者治疗失败的首要原因.中高度恶性PBNHL治疗可采用乳腺局部切除加全身化疗和乳腺放疗,宜接受中枢预防治疗,应密切监测对侧乳腺病变,及时治疗.     

Primary Non-Hodgkin Malignant Lymphoma of the Male Breast

A case of primary non-Hodgkin lymphoma of the male breast isreported. The patient was a 76-year-old Japanese with a historyof bilateral gynecomastia. After the patient had received sexhormone treatment for the gynecomastia, rapid growth of a tumorin the right breast was noted, with regression of a contralateralbreast lesion. Clinically, inflammatory breast cancer was suspected,and right mastectomy with ipsilateral axillary lymph node dissectionwas performed after intraarterial infusion chemotherapy usinga cis-platinum derivative. The histology of the surgical specimenwas non-Hodgkin malignant lymphoma of the diffuse large celltype, with focal tumor necrosis. Immunohistochemically, thetumor cells showed a B-cell nature. The patient is currentlywell without disease 39 months after surgery.     

原发中枢神经系统淋巴瘤临床特点与疗效:40例分析

背景与目的:原发中枢神经系统淋巴瘤(primary central nervous system lymphoma,PCNSL)近年来在免疫功能正常的人群中发病率有所上升。本研究的目的是探讨PCNSL的临床特征、治疗及预后。方法:回顾性分析经病理证实的40例PCNSL的临床资料。结果:40例患者中24例(60.0%)主要表现为颅内高压;21例(52.5%)单发病灶;28例(70.0%)为弥漫大B细胞淋巴瘤。12例(30.0%)手术全切肿瘤,中位KPS评分70;14例(35.0%)接受HD-MTX为主的化疗加全脑放疗;19例(47.5%)接受鞘内化疗。40例患者Kaplan-Meier分析总中位生存时间为26个月,2年生存率65.2%;HD-MTX联合全脑放疗组患者完全缓解率73.3%,中位生存时间38.5个月,2年生存率80.6%。结论:PCNSL患者临床表现主要为颅内压增高,单发病灶多见,B细胞亚型多见,HD-MTX联合适当剂量的全脑放射治疗可延长生存期,年龄、术后KPS评分影响预后。     

Concomitant Primary Low Grade Non-Hodgkin's Lymphoma of the Spleen and Breast Carcinoma

A case is described of a 71 year old woman with scirrhous breast cancer and multiple hypoechogenic lesions in the spleen. The patient was treated successfully by mastectomy and splenectomy. Morphologic examination of the spleen showed a primary, centroblastic-centrocytic, low grade non-Hodgkin's lymphoma. Eight months after splenectomy the patient still remains in complete remission.     

13例伯基特和伯基特样淋巴瘤的临床特点分析

目的：分析伯基特淋巴瘤（BL）和伯基特样淋巴瘤（BLL）的临床特点,总结疗效,探讨可能的最佳方案和治疗相关合并症。方法：回顾性分析北京肿瘤医院1996年8 月至2008年10月收治的13例经病理确诊为伯基特淋巴瘤和伯基特样淋巴瘤患者的临床资料。所有患者均接受化疗为主的治疗方案,评价疗效和不良反应。结果：13例患者中,男12例,女1 例;发病年龄11～62岁,中位年龄15岁;Ⅰ期3 例,Ⅱ期2 例,Ⅲ期2 例,Ⅳ期6 例,其中晚期（Ⅲ、Ⅳ期）病例占61.5% ,初治时发生骨髓侵犯2 例（15.4%）,中枢神经系统侵犯4 例（30.8%）;常见的侵犯部位为浅表淋巴结（61.5%）、腹腔脏器（53.8%）和腹腔及腹膜后淋巴结（38.5%）;有B 症状7 例（53.8%）;8/10例（80.0%）血清乳酸脱氢酶（LDH ）水平升高,1/10例血清尿酸升高;病理示BL11例,BLL 2 例。11例患者获得完全缓解或未经证实的完全缓解,1 例部分缓解,总有效率为92.3% 。中位随访时间8 个月（5～35个月）,至随访截止6 例患者死亡,1 例失访。1 年总生存率（OS）、无进展生存率（PFS）和无瘤生存率（DFS）分别为 56.98%、32.31%和39.77%。化疗中Ⅲ～Ⅳ度骨髓抑制发生率为69.2% ,1 例患者出现肿瘤溶解综合征和Ⅳ度全消化道黏膜炎。结论：推荐高强度短疗程化疗方案作为BL和BLL 的一线治疗,应积极预防处理化疗不良反应。     

原发乳腺非霍奇金淋巴瘤6例临床分析

目的 分析原发乳腺非霍奇金淋巴瘤的临床特点,探讨诊断、分期和治疗方法及其预后的影响因素。方法 回顾性分析6例原发乳腺非霍奇金淋巴瘤的临床资料。6例病例均获随访,均于手术局部切除后辅助化疗和（或）放疗。结果 6例的中位生存期为53．5个月,均无瘤生存。结论 与原发乳腺非霍奇金淋巴瘤预后密切相关的因素依次是临床分期、病理类型和原发肿瘤大小、对原发乳腺非霍奇金淋巴瘤行综合治疗,可取得满意疗效。     

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

Follicular lymphoma (FL) is the second most common non‐Hodgkin lymphoma (NHL) subtype. The histological transformation (HT) of FL is an event considered frequent in the natural history of this tumor. We studied the transformation rates, predictive factors, and treatment characteristics that may impact in the survival of patients with FL and HT. A total of 1074 patients diagnosed with FL were prospectively enrolled from 1990 to 2016 in a Spanish registry. Sixty‐four HTs were recorded based on clinical criteria (55%) or histological confirmation (45%). The cumulative incidence rate of transformation at 5 years is 7.3%. The 5‐year overall survival (OS) without HT was 85% (95% confidence interval [CI], 70%‐90%) vs 66% (95% CI, 51%‐76%; P = 0.0012) with HT. Factors associated with HT were elevated lactate dehydrogenase (LDH) (odds ratio [OR] 1.83), intermediate‐high Follicular lymphoma international prognostic index (FLIPI) (OR 2.16‐OR 3.21), B symptoms (OR 2.46), or Eastern Cooperative Oncology Group (ECOG) 1 (OR 2.35). Treatment options related to HT were “watch and wait” or no rituximab or anthracyclines initially. A 5‐year OS for patients treated with chemotherapy before HT was 55% (95% CI, 38%‐69%) versus 81% (95% CI, 53%‐93%; P = 0.009) for those who had not received it. The HT rate has decreased after the introduction of rituximab, as has been previously described. The timing of this treatment had an impact on the survival of these patients.     

Primary Breast Lymphoma(PBL):A Literature Review

Primary breast lymphoma is a rare disease.It is mainly found in female patients,the right breast in more frequently involved.The majority of PBL are diagnosed by biopsy or postoperative pathological findings.The combined therapy regimen,the main part of which is CHOP chemotherapy,is the main stream.Radical surgery is to be avoided.     

乳腺原发非何杰金淋巴瘤临床病理及免疫组化分析(附8例报告)

收集8例乳腺原发性非何杰金淋巴瘤进行回顾性研究。6例临床诊断乳腺癌并行根治术，其中4例术中冰冻切片，均误诊为髓样痛和低分化癌。7例作了免疫组化检查，LCA全部阳性，其中6例L26阳性，1例UCHL1阳性，余1例为髓外装细胞瘤．提示乳腺恶性淋巴瘤多数为B淋巴细胞性。研究结果显示：本病在临床和病理诊断中易误诊为乳腺癌，免疫组化有助于鉴别诊断。     

原发性乳腺淋巴瘤(15例报告及文献复习)

目的：总结原发性乳腺淋巴瘤（PBL）的临床特征并探讨其预后因素。方法：回顾性分析15例PBL的临床资料并复习同期国内文献共134例报告,运用SPSS软件包分析其预后因素。结果：15例PBL均为术后明确诊断。中位年龄42岁,全部为NHL,其中DLCL型占53．33％,10例右乳首发,文献统计分析显示右乳多发（59％）,且乳房肿块大小和治疗模式是重要的预后因素,而与年龄、左或右乳首发分组其生存期无显著差别。结论：PBL以NHL占绝大多数,右乳首发多见,术前诊断困难,治疗宜选择手术联合放疗或（和）化疗的综合治疗模式。     

Primary Ovarian Lymphoma: Report of Two Cases and Review of the Literature

Abstract

Ovarian lymphoma is a rare entity. Clinicians should be aware of its clinical manifestations and management since surgery alone often is not adequate treatment. Here, we present two cases of ovarian lymphoma and discuss what is known about ovarian lymphoma.     

睾丸恶性淋巴瘤12例临床分析

目的 探讨睾丸恶性淋巴瘤的诊治经验，以提高患者生存率。方法 对12例睾丸恶性淋巴瘤患者的临床资料进行分析。结果 该病的主要临床特点为无痛性睾丸肿大，确诊后行根治性睾丸切除术及放化疗，化疗方案以CHOP、CHOP—B、CHOP-E和HEPP为主。结论 该病恶性程度高，预后差，应积极进行综合治疗，以提高患者生存率。     

乳腺原发性恶性淋巴瘤：附9例报告

本文报告9例经病理证实的乳腺原发性恶性淋巴瘤,占同期乳腺恶性肿瘤0.55％。9例中肿块切除3例次,全乳腺切除5例次,根治术3例次。8例化疗,其中1例辅助放疗。随访率88.9％(8/9)。5年生存率33.3％(2/6)。本组病例特点:年轻患者较多,且恶性程度高;双侧乳腺发病率高;肿块多为非浸润性且生长迅速;皮肤肌肉、腋淋巴结受累少,较早出现全身播散。预后明显较乳腺癌差。作者认为根治术加化疗的疗效相对较好。     

原发性甲状腺恶性淋巴瘤10例临床分析

目的：总结原发性甲状腺恶性淋巴瘤的诊断和治疗经验。方法：通过对本院10例原发性甲状腺恶性淋巴瘤的回顾性分析,总结其临床特点及治疗体会：结果：原发性甲状腺恶性淋巴瘤属罕见肿瘤,多种手段综合治疗可提高疗效。结论：术中病理提示为恶性淋巴瘤,应避免行甲状腺癌联合根治术;行肿瘤切除术后或姑息切除术后配合放、化疗,可达到较好疗效。